The Determinants of HIV Treatment Costs in Resource Limited Settings

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Menzies, Nicolas A ^a,b,c   Berruti, Andres A ^a   Blandford, John M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ICF INTERNATIONAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CLINIC VISIT FREQUENCY; CLINICIAN PATIENT RATIO; COST BENEFIT ANALYSIS; DRUG COST; ETHIOPIA; FOLLOW UP; FUNDING; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; GROSS NATIONAL PRODUCT; HEALTH CARE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE NEED; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MOZAMBIQUE; NIGERIA; PATIENT CARE; PATIENT MONITORING; PATIENT VOLUME; PREDICTOR VARIABLE; PUBLIC-PRIVATE PARTNERSHIP; SITE MATURITY; TREATMENT DURATION; UGANDA; VIET NAM;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BOTSWANA; DELIVERY OF HEALTH CARE; ETHIOPIA; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LINEAR MODELS; MOZAMBIQUE; NIGERIA; UGANDA; VIETNAM;

EID: 84868674725     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048726     Document Type: Article

References (35)

1. UNAIDS (2010) UNAIDS Report on the Global AIDS Epidemic 2010. Geneva: UNAIDS.
2. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach -2010 Revision. Geneva: WHO.
3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
4. Holmes CB, Atun R, Avila C, Blandford JM, (2011) Expanding the generation and use of economic and financial data to improve HIV program planning and efficiency: a global perspective. J Acquir Immune Defic Syndr 57Suppl 2: S104-108.
5. Walker DG, Over M, Bertozzi SM, (2011) Can cost studies improve the performance of donor-financed HIV treatment? AIDS 25: 1795-1796.
6. Médecins Sans Frontières (2011) Untangling the Web of Antiretroviral Price Reductions -14th Edition. Geneva: Médecins Sans Frontières.
7. Perez-Casas C, Mace C, Berman D, Double J (2001) Accessing ARVs: untangling the web of price reductions for developing countries. Geneva: Médecins Sans Frontières.
8. Oliva-Moreno J, Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, (2010) Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain. Eur J Health Econ 11: 405-412.
9. Long L, Fox M, Sanne I, Rosen S, (2010) The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 24: 915-919.
10. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, et al. (2005) Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 43: III40-52.
11. Galarraga O, Wirtz VJ, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, et al. (2011) Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics 29: 579-599.
12. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, et al. (2011) The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25: 1753-1760.
13. Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, et al. (2006) Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 3: e4.
14. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, et al. (2008) Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 168: 1910-1918.
15. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 355: 1141-1153.
16. Rosen S, Long L, Fox M, Sanne I, (2008) Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 48: 334-344.
17. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, et al. (2008) Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371: 1443-1451.
18. Cleary SM, McIntyre D, Boulle AM, (2008) Assessing efficiency and costs of scaling up HIV treatment. AIDS 22 (Suppl 1): S35-42.
19. Meyer-Rath G, Over M, (2012) HIV Treatment as Prevention: Modelling the Cost of Antiretroviral Treatment-State of the Art and Future Directions. PLoS Med 9: e1001247.
20. Rosen S, Long L, Sanne I, (2008) The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health 13: 1005-1015.
21. Harling G, Wood R, (2007) The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 45: 348-354.
22. Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, et al. (2011) Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med 8: e1001055.
23. Meyer-Rath G, Miners A, Santos AC, Variava E, Venter WD (2012) Cost and resource use of patients on antiretroviral therapy in the urban and semi-urban public sectors of South Africa. J Acquir Immune Defic Syndr. In press.
24. Filler SJ, Berruti AA, Menzies N, Berzon R, Ellerbrock TV, et al. (2011) Characteristics of HIV care and treatment in PEPFAR-supported sites. J Acquir Immune Defic Syndr 57: e1-6.
25. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258.
26. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of healthcare programmes: Third edition. Oxford: Oxford University Press.
27. World Bank (2011) World Development Indicators 2011. Washington, DC: World Bank.
28. Adam T, Evans DB, Murray CJ, (2003) Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1: 3.
29. Hadfield JD, (2010) MCMC Methods for Multi-Response Generalized Linear Mixed Models: The MCMCglmm R Package. Journal of Statistical Software 33: 1-22.
30. R Development Core Team (2008) R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
31. Manning WG, (1998) The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 17: 283-295.
32. Manning WG, Mullahy J, (2001) Estimating log models: to transform or not to transform? J Health Econ 20: 461-494.
33. WHO (2011) Global Price Reporting Mechanism. Geneva: WHO. Available: http://www.who.int/hiv/amds/gprm/en/. Accessed 2011 May 21.
34. Freedberg KA, Scharfstein JA, Seage GR 3rd, Losina E, Weinstein MC, et al (1998) The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 279: 130-136.
35. Pitter C, Kahn JG, Marseille E, Lule JR, McFarland DA, et al. (2007) Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J Acquir Immune Defic Syndr 44: 336-343.